Consequences of Oral Anticoagulants for Stroke Risk Reduction in Atrial Fibrillation: Where Do We Go from Here?
Boston Scientific financially supported the development of this paper and the roundtable discussion of its contributors.
Recently, several multidisciplinary experts participated in a virtual roundtable in partnership with The Heart Rhythm Society to discuss the costs and challenges of preventing atrial fibrillation (Afib) related strokes. Pulling from the vantage points of their respective areas of expertise, along with findings from previously published medical literature, we have developed a white paper to assist healthcare professionals in understanding the consequences, direct and indirect, of oral anticoagulant (OAC) therapy for stroke risk reduction in patients with Afib. The white paper also describes key data regarding non-pharmacological alternatives for those with the heart condition.
Download the full white paper, titled "Consequences of Oral Anticoagulants for Stroke Risk Reduction in Atrial Fibrillation: Where Do We Go from Here?"